Vanda (VNDA) Ramps; Lazard Sees Upside

May 24, 2013 11:54 AM EDT Send to a Friend
Get Alerts VNDA Hot Sheet
Price: $11.11 +7.55%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade VNDA Now!
Join SI Premium – FREE
Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) ramped on Friday. The move is being traced to "exceptionally positive" feedback for Vanda's experimental tasimelteon to treat non-24-hour disorder.

Feedback was pointed out by analyst Joshua Schimmer of Lazard Capital. He thinks Vanda is well ahead of the game in raising awareness about non-24 hour. He also sees plenty of upside in the stock.

Lazard has a Buy rating on Vanda Pharmaceuticals with a price target of $17.00.

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals (NASDAQ: VNDA) click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $7.12 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Lazard

Add Your Comment